Thomas Taapken

Thomas Taapken

Director of Finance/CFO at INFLARX N.V.

Net worth: 7 455 $ as of 31/08/2026

61 year
Health Technology
Finance
Commercial Services

Profile

Thomas Taapken is currently Chief Executive Officer at Bluehaven Therapeutics AG, Chairman at ImCyse SA since 2019, Director at SciBase AB since 2017, Chief Financial Officer at elbion NV, and Chief Financial Officer at InflaRx NV since 2020.
Former positions include CEO, CFO & Investor Relations Contact at Biotie Therapies Oy from 2008 to 2011; Independent Director at Memo Therapeutics AG from 2021 to 2023; Partner at Burrill LLC from 1998 to 2002; Chief Executive & Financial Officer at MediGene AG from 2017 to 2018; Chief Executive & Financial Officer at Epigenomics AG from 2011 to 2016; Chief Financial Officer at elbion AG in 2007; Director at Immunic AG; Independent Director at SciBase Holding AB; Partner at DVC Deutsche Venture Capital; and Principal at Sanofi-Aventis Deutschland GmbH.
Education includes a doctorate from the Technical University of Berlin conferred in 1994.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
18/03/2026 3,500 ( 0% ) 7 455 $ 31/08/2026

Thomas Taapken active positions

CompaniesPositionStart
INFLARX N.V. Director of Finance/CFO 01/10/2020
Director of Finance/CFO -
Chairman 01/01/2019
Bluehaven Therapeutics AG
Chief Executive Officer -
Scibase AB
Director/Board Member 01/01/2017

Former positions of Thomas Taapken

CompaniesPositionEnd
Director/Board Member 01/12/2023
MEDIGENE AG Chief Executive Officer 31/08/2018
EPIGENOMICS AG Chief Executive Officer 30/06/2016
BIOTIE THERAPIES CORP Chief Executive Officer 01/04/2011
░░░░░░ ░░ ░░░░░░░░ ░░ ░░░░░░░░░░░ ░░░░░░░░░░
See the detail of Thomas Taapken's experience

Training of Thomas Taapken

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

73

1st degree connections

16

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies16

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Commercial Services

Consumer Services

Health Technology

Health Technology

Scibase AB

Health Technology

Health Technology

Health Technology

Bluehaven Therapeutics AG

  1. Stock Market
  2. Insiders
  3. Thomas Taapken
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!